Immune globulin - Therapure Biopharma

Drug Profile

Immune globulin - Therapure Biopharma

Alternative Names: 10% intravenous immunoglobulin - Therapure Biopharma; Human immunoglobulin - Therapure Biopharma; Intravenous immunoglobulin - Therapure Biopharma; PlasmaCap IG; Therapure PlasmaCap IG

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therapure Biopharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 05 Sep 2017 Phase-III clinical trials in Immunodeficiency disorders (In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT03238079)
  • 05 Aug 2017 Therapure Biopharma plans a phase III trial for Immunodeficiency disorders (In children, In adolescents, In adults, In the elderly) in USA (IV) in August 2017 (NCT03238079)
  • 05 Aug 2017 Preclinical trials in Immunodeficiency disorders in USA (IV), before August 2017 (Therapure Biopharma website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top